Type 1 Diabetes and mild cognitive impairment

Mild cognitive impairment: another complication of Diabetes mellitus type 1?

Diabetes Mellitus (DM) is often considered a risk factor for mild cognitive impairment (MCI) and the association between these pathologies has been well established by several clinical studies [1, 2]. However, this relationship has mainly been studied in patients suffering from Type 2 Diabetes.

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Dr. Grit Andersen on Feb 4, 2020 5:17:00 PM

Free webinar on early phase obesity research

Profil continues the successful series of scientific webinars. On February 19th, 2020 we will air our free webinar on early phase obesity research. The session is presented by Dr. Daniela Lamers, Nutritional Science Specialist at Profil. 

Read More

Topics: About Profil

Posted by Svenya Meister on Jan 21, 2020 4:50:00 PM

Trustworthy AI in healthcare - it's TIME TO DELIVER

In Europe chronic diseases account for 86% of deaths and 77% of disease burden, thereby creating a tremendous challenge on societies. At the same time digitisation is bringing huge technological and cultural opportunities. In healthcare the usage of data-driven forecasts on individual and population health as by integration of artificial intelligence (AI)-enabled algorithms has the potential to revolutionise health protection and chronic care provision while securing the sustainability of healthcare systems.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Jan 7, 2020 5:16:00 PM

Profil wishes merry christmas and a happy new year 2020

Another year has passed and the Profil blog has seen many interesting articles through the last months. We have posted about events, conferences, webinars, and interesting scientific topics for clinical diabetes researchers. 

Read More

Topics: About Profil

Posted by Svenya Meister on Dec 23, 2019 3:56:00 PM

Beer or wine or both – and if both, in which order?

Recent study investigates the impact of the combination and order of beer and wine on hangover severity

“Beer before wine and you’ll feel fine, wine before beer and you’ll feel queer” or in German “Bier auf Wein, das lass sein; Wein auf Bier, das rat’ ich dir” – this seems to be a common folk wisdom and regularly used recommendation with regards to alcohol beverage consumption in many countries and languages.

But is this just a saying or do we have scientific proof for this concept? Scientists from the University of Witten/Herdecke and the University of Cambridge investigated this old folklore and published the results in the American Journal of Clinical Nutrition early this year [1].

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Daniela Lamers on Dec 10, 2019 5:11:00 PM

Profil World - The clinical diabetes research newsletter - November 2019

Dear all,

Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.

Read More

Topics: About Profil

Posted by Svenya Meister on Nov 26, 2019 5:18:00 PM

Lipohypertrophy – New insights into an old issue?

Lipohypertrophy (LH) is a common side effect of insulin therapy in patients with diabetes mellitus. The prevalence of lipohypertrophy is high with cross-sectional studies reporting up to 64% of patients being affected, with higher numbers in type 1 diabetes. Predisposing factors for the development of lipohypertrophy include duration of insulin treatment, needle reuse frequency, BMI and incorrect injection and site rotation techniques. Particularly the latter seem to be of major importance as re-education of patients in proper injection site rotation with avoidance of LH tissue was reported to improve glycaemic control [1].

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Dr. Susanne Famulla on Nov 14, 2019 5:16:00 PM

What news in the treatment of Type 2 diabetes was presented at EASD 2019?

The annual meeting of the European Association for the Study of Diabetes (EASD) took place this year in Barcelona, Spain. The present text offers a selection of topics relevant for the field of type 2 diabetes mellitus (T2DM) discussed during that meeting.

Read More

Topics: The Science behind Diabetes, Treating Diabetes

Posted by Dr. Jorge Arrubla on Oct 17, 2019 5:30:00 PM

Finally breakthrough in the immunological approach to type 1 diabetes

Type 1 diabetes is a T-cell mediated autoimmune disease. For more than 40 years, researchers have tried to intervene in the autoimmune process to halt or perhaps even reverse the slow destruction of insulin producing beta cells [1]. This has proven an elusive goal, but very recently FDA granted a breakthrough therapy designation to teplizumab, an anti-CD3 monoclonal antibody  [2]. The drug modifies CD8+ T lymphocytes, which are thought to be the key effector cells that kill beta cells.

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Prof. Hans de Vries on Oct 1, 2019 4:58:00 PM

Current developments in approaches to bridging studies

Waiving Bridging studies under certain circumstances for biosimilar applications?

A bridging study is a study performed in a new region to provide pharmacodynamic or clinical data on efficacy, safety, dosage and dose regimen that will allow extrapolation of foreign clinical data to the population in the new region [1]. However, in most cases bridging studies between an original product versus a so called foreign reference or a local reference product generate costs without providing any notable benefit for the specific patient, nor notable scientific output. 

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes, Diabetes Technology

Posted by Dr. Grit Andersen on Sep 17, 2019 5:25:00 PM

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts